Two Compounds, Many Brand Names
The GLP-1 receptor agonist market — one of the most consequential pharmaceutical developments in recent memory — can be confusing at first glance. Between Ozempic, Wegovy, Mounjaro, and Zepbound, consumers and investors alike might feel overwhelmed. But the landscape is simpler than it appears: there are really only two core compounds driving this revolution. Semaglutide powers both Ozempic and Wegovy (Novo Nordisk's offerings), while tirzepatide is the molecule behind Mounjaro and Zepbound (Eli Lilly's products). Understanding this distinction is key to evaluating who is actually winning.
Efficacy as the Deciding Factor
In pharmaceuticals, effectiveness is king — and right now, tirzepatide holds the crown. Zepbound is widely regarded as the most effective GLP-1 product on the market. Novo Nordisk recently launched a higher-dose version of Wegovy in the U.S. at a cash price of $399, which undercuts Zepbound's higher doses by roughly $100. However, this higher dose of Wegovy only brings its efficacy close to what Zepbound already achieves at standard dosing. The natural question arises: why would a patient opt for a very high dose of one drug just to match the effectiveness of a competitor's standard offering?
Until a product demonstrates dramatically superior effectiveness over Zepbound, tirzepatide is likely to remain the market leader. Efficacy, above all else — price, branding, first-mover advantage — is the primary driver of market share in this space.
Eli Lilly's Strengthening Competitive Position
What makes Eli Lilly's position particularly formidable is not just its current product but its pipeline. The company has a compound in late-stage development called retatrutide, which appears to be the only product in advanced trials showing results potentially superior to Zepbound — with weight loss figures approaching 28% to 30%.
Lilly's strategy is to offer a full menu of options across the weight-loss spectrum: retatrutide for more extreme cases, Zepbound as the mainline treatment, and a recently approved pill form for patients seeking a lower-intensity option. No other company currently matches this breadth of offerings, which gives Lilly a uniquely comprehensive position in the market.
Novo Nordisk: The First Mover Under Pressure
Novo Nordisk deserves credit as the pioneer that brought GLP-1 therapies into the mainstream. However, being first does not guarantee lasting dominance. When products are lined up side by side, it is difficult to argue that Novo's offerings are superior to Lilly's.
Novo has responded by competing aggressively on price — a strategy that implicitly acknowledges its efficacy gap. The $399 pricing for higher-dose Wegovy and the $25 insurance copay are clearly designed to attract price-sensitive patients willing to trade some efficacy for a lower cost. Novo has also expanded its injectable range and secured approval for a pill version of semaglutide, a long-anticipated development for 2026. These moves are smart, but they are largely defensive.
The Price War and Expanding Demand
As more manufacturers enter the GLP-1 space, prices will naturally continue to decline. This is significant because a substantial portion of the market consists of cash-pay customers — people without commercial insurance coverage for these drugs. For this segment, price sensitivity is considerably higher than for typical pharmaceuticals.
Lower prices mean expanded access, which means growing demand. The supply shortages that plagued the market in prior years are a testament to the enormous unmet demand. As pricing drops and supply stabilizes, the total addressable market will only expand.
Pills vs. Injectables: A Common Misconception
A frequent question is whether pill forms will eventually replace injectables. The answer, counterintuitively, is no. Injectables will continue to be the primary course of treatment for several reasons. First, they are simply more effective. Second, many GLP-1 users are diabetes patients already accustomed to injections. Third, the injectable format requires only a once-weekly painless injection — and next-generation products may reduce that to once a month.
The pill serves a complementary role: it captures patients who categorically refuse needles, and it can be launched in new markets more cheaply than injectables. But the bulk of revenue will continue to flow from injectable products.
The Emerging Challengers
Most of big pharma wants a piece of the GLP-1 market, and several notable players are developing competing products. Amgen is working on maratide, a product with a different mechanism of action that would require less frequent dosing. Pfizer has made an acquisition targeting a similar less-frequent injectable. Roche has reported promising phase two or three trial results.
However, none of these products currently appear to be more effective than Zepbound. They may carve out niches — perhaps serving patients who prefer less frequent injections — but they are unlikely to dethrone the current leaders anytime soon.
The Financial Picture
From a credit and balance sheet perspective, Eli Lilly currently carries a positive outlook. The company is investing heavily in new manufacturing facilities, R&D, and some M&A activity, but the sheer scale of its growth means debt leverage has essentially nowhere to go but down. The balance sheet is expected to continue improving.
Novo Nordisk, by contrast, holds a stable outlook. It entered this race with lower leverage than Lilly, so while its financial position is solid, there is less of an improvement trajectory to highlight. The credit story, like the product story, currently favors Lilly.
Conclusion
The GLP-1 market is one of the most dynamic and consequential arenas in modern pharmaceuticals. While Novo Nordisk lit the spark, Eli Lilly has built the stronger fire. With superior efficacy in its current flagship, the most promising pipeline in development, and a strengthening financial position, Lilly is positioned as the company to beat. The race is far from over — new entrants, pricing pressures, and pipeline surprises could shift the landscape — but as things stand today, efficacy remains the north star, and Eli Lilly's tirzepatide franchise is pointing directly at it.